Association between serum gamma-glutamyltransferase and early-onset coronary artery disease: a retrospective case-control study

References

• Couto N, Wood J, Barber J. The role of glutathione reductase and related enzymes on cellular redox homoeostasis network. Free Radic Biol Med. 2016;95:1–9. doi: 10.1016/j.freeradbiomed.2016.02.028.
   PubMed Web of Science ®Google Scholar
• Lee DH, Ha MH, Kim JH, et al. Gamma-glutamyltransferase and diabetes – a 4 year follow-up study. Diabetologia. 2003;46(3):359–364. doi: 10.1007/s00125-003-1036-5.
   PubMed Web of Science ®Google Scholar
• Grimm C, Hofstetter G, Aust S, et al. Association of gamma-glutamyltransferase with severity of disease at diagnosis and prognosis of ovarian cancer. Br J Cancer. 2013;109(3):610–614. doi: 10.1038/bjc.2013.323.
   PubMed Web of Science ®Google Scholar
• Kunutsor SK, Laukkanen JA. Gamma-glutamyltransferase and risk of chronic kidney disease: a prospective cohort study. Clin Chim Acta. 2017;473:39–44. doi: 10.1016/j.cca.2017.08.014.
   PubMed Web of Science ®Google Scholar
• Lawlor DA, Sattar N, Smith GD, et al. The associations of physical activity and adiposity with alanine aminotransferase and gamma-glutamyltransferase. Am J Epidemiol. 2005;161(11):1081–1088. doi: 10.1093/aje/kwi125.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Xin X, Luo XP. The relationship between the ratio of gamma-glutamyltransferase to high-density lipoprotein cholesterol and the risk of diabetes mellitus using publicly available data: a secondary analysis based on a longitudinal study in Japan. Lipids Health Dis. 2023;22(1):7. doi: 10.1186/s12944-023-01772-9.
   PubMed Web of Science ®Google Scholar
• Bonnet F, Gastaldelli A, Pihan-Le Bars F, et al. Gamma-glutamyltransferase, fatty liver index and hepatic insulin resistance are associated with incident hypertension in two longitudinal studies. J Hypertens. 2017;35(3):493–500. doi: 10.1097/HJH.0000000000001204.
   PubMed Web of Science ®Google Scholar
• Corti A, Belcastro E, Dominici S, et al. The dark side of gamma-glutamyltransferase (GGT): pathogenic effects of an ‘antioxidant’ enzyme. Free Radic Biol Med. 2020;160:807–819. doi: 10.1016/j.freeradbiomed.2020.09.005.
   PubMed Web of Science ®Google Scholar
• Franzini M, Corti A, Martinelli B, et al. Gamma-glutamyltransferase activity in human atherosclerotic plaques – biochemical similarities with the circulating enzyme. Atherosclerosis. 2009;202(1):119–127. doi: 10.1016/j.atherosclerosis.2008.03.023.
   PubMed Web of Science ®Google Scholar
• Kengne AP, Czernichow S, Stamatakis E, et al. Gamma-glutamyltransferase and risk of cardiovascular disease mortality in people with and without diabetes: pooling of three British Health Surveys. J Hepatol. 2012;57(5):1083–1089. doi: 10.1016/j.jhep.2012.06.034.
   PubMed Web of Science ®Google Scholar
• Breitling LP, Claessen H, Drath C, et al. Gamma-glutamyltransferase, general and cause-specific mortality in 19,000 construction workers followed over 20 years. J Hepatol. 2011;55(3):594–601. doi: 10.1016/j.jhep.2010.12.029.
   PubMed Web of Science ®Google Scholar
• Koehler EM, Sanna D, Hansen BE, et al. Serum liver enzymes are associated with all-cause mortality in an elderly population. Liver Int. 2014;34(2):296–304. doi: 10.1111/liv.12311.
   PubMed Web of Science ®Google Scholar
• Du G, Song Z, Zhang Q. Gamma-glutamyltransferase is associated with cardiovascular and all-cause mortality: a meta-analysis of prospective cohort studies. Prev Med. 2013;57(1):31–37. doi: 10.1016/j.ypmed.2013.03.011.
   PubMed Web of Science ®Google Scholar
• Hauser ER, Crossman DC, Granger CB, et al. A genomewide scan for early-onset coronary artery disease in 438 families: the GENECARD study. Am J Hum Genet. 2004;75(3):436–447. doi: 10.1086/423900.
   PubMed Web of Science ®Google Scholar
• Cipriani V, Mannucci PM, Ardissino D, et al. Familial aggregation of early-onset myocardial infarction. Eur J Intern Med. 2010;21(6):511–515. doi: 10.1016/j.ejim.2010.07.017.
   PubMed Web of Science ®Google Scholar
• Cole JH, Miller JI3rd, Sperling LS, et al. Long-term follow-up of coronary artery disease presenting in young adults. J Am Coll Cardiol. 2003;41(4):521–528. doi: 10.1016/s0735-1097(02)02862-0.
   PubMed Web of Science ®Google Scholar
• Schoenenberger AW, Radovanovic D, Stauffer JC, et al. Acute coronary syndromes in young patients: presentation, treatment and outcome. Int J Cardiol. 2011;148(3):300–304. doi: 10.1016/j.ijcard.2009.11.009.
   PubMed Web of Science ®Google Scholar
• Rampidis GP, Benetos G, Benz DC, et al. A guide for Gensini score calculation. Atherosclerosis. 2019;287:181–183. doi: 10.1016/j.atherosclerosis.2019.05.012.
   PubMed Web of Science ®Google Scholar
• Schumann G, Bonora R, Ceriotti F, et al. IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37 °C. International Federation of Clinical Chemistry and Laboratory Medicine. Part 6. Reference procedure for the measurement of catalytic concentration of gamma-glutamyltransferase. Clin Chem Lab Med. 2002;40(7):734–738. doi: 10.1515/CCLM.2002.126.
   PubMed Web of Science ®Google Scholar
• Perrin-Sarrado C, Pongas M, Dahboul F, et al. Reduced activity of the aortic gamma-glutamyltransferase does not decrease S-nitrosoglutathione induced vasorelaxation of rat aortic rings. Front Physiol. 2016;7:630. doi: 10.3389/fphys.2016.00630.
   PubMed Web of Science ®Google Scholar
• Møller S, Bernardi M. Interactions of the heart and the liver. Eur Heart J. 2013;34(36):2804–2811. doi: 10.1093/eurheartj/eht246.
   PubMed Web of Science ®Google Scholar
• Lee H, Lee YH, Kim SU, et al. Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: a nationwide cohort study. Clin Gastroenterol Hepatol. 2021;19(10):2138–2147.e10. doi: 10.1016/j.cgh.2020.12.022.
   PubMed Web of Science ®Google Scholar
• Duell PB, Welty FK, Miller M, et al. Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2022;42(6):e168–e185.
   PubMed Web of Science ®Google Scholar
• Kabłak-Ziembicka A, Badacz R, Przewłocki T. Clinical application of serum microRNAs in atherosclerotic coronary artery disease. J Clin Med. 2022;11(22):6849. doi: 10.3390/jcm11226849.
   PubMed Web of Science ®Google Scholar
• Márquez AB, van der Vorst E, Maas SL. Key chemokine pathways in atherosclerosis and their therapeutic potential. J Clin Med. 2021;10(17):3825. doi: 10.3390/jcm10173825.
   PubMed Web of Science ®Google Scholar
• Oestreicher J, Morgan B. Glutathione: subcellular distribution and membrane transport. Biochem Cell Biol. 2019;97(3):270–289. doi: 10.1139/bcb-2018-0189.
   PubMedGoogle Scholar
• Stark AA, Zeiger E, Pagano DA. Glutathione metabolism by gamma-glutamyltranspeptidase leads to lipid peroxidation: characterization of the system and relevance to hepatocarcinogenesis. Carcinogenesis. 1993;14(2):183–189. doi: 10.1093/carcin/14.2.183.
   PubMed Web of Science ®Google Scholar
• Incalza MA, D'Oria R, Natalicchio A, et al. Oxidative stress and reactive oxygen species in endothelial dysfunction associated with cardiovascular and metabolic diseases. Vascul Pharmacol. 2018;100:1–19. doi: 10.1016/j.vph.2017.05.005.
   PubMed Web of Science ®Google Scholar
• Daiber A, Chlopicki S. Revisiting pharmacology of oxidative stress and endothelial dysfunction in cardiovascular disease: evidence for redox-based therapies. Free Radic Biol Med. 2020;157:15–37. doi: 10.1016/j.freeradbiomed.2020.02.026.
   PubMed Web of Science ®Google Scholar
• Gresele P, Momi S, Guglielmini G. Nitric oxide-enhancing or -releasing agents as antithrombotic drugs. Biochem Pharmacol. 2019;166:300–312. doi: 10.1016/j.bcp.2019.05.030.
   PubMed Web of Science ®Google Scholar
• Volpe C, Villar-Delfino PH, Dos Anjos P, et al. Cellular death, reactive oxygen species (ROS) and diabetic complications. Cell Death Dis. 2018;9(2):119. doi: 10.1038/s41419-017-0135-z.
   PubMed Web of Science ®Google Scholar
• Paolicchi A, Minotti G, Tonarelli P, et al. Gamma-glutamyl transpeptidase-dependent iron reduction and LDL oxidation – a potential mechanism in atherosclerosis. J Investig Med. 1999;47(3):151–160.
   PubMed Web of Science ®Google Scholar
• Jiang H, Zhou Y, Nabavi SM, et al. Mechanisms of oxidized LDL-mediated endothelial dysfunction and its consequences for the development of atherosclerosis. Front Cardiovasc Med. 2022;9:925923. doi: 10.3389/fcvm.2022.925923.
   PubMed Web of Science ®Google Scholar
• Chung HS, Lee JS, Kim JA, et al. γ-glutamyltransferase variability and the risk of mortality, myocardial infarction, and stroke: a nationwide population-based cohort study. J Clin Med. 2019;8(6):832.
   PubMed Web of Science ®Google Scholar
• Kasapoglu B, Turkay C, Bayram Y, et al. Role of GGT in diagnosis of metabolic syndrome: a clinic-based cross-sectional survey. Indian J Med Res. 2010;132:56–61.
   PubMed Web of Science ®Google Scholar
• Xuan C, Bai XY, Gao G, et al. Association between polymorphism of methylenetetrahydrofolate reductase (MTHFR) C677T and risk of myocardial infarction: a meta-analysis for 8,140 cases and 10,522 controls. Arch Med Res. 2011;42(8):677–685. doi: 10.1016/j.arcmed.2011.11.009.
   PubMed Web of Science ®Google Scholar
• Zhang SY, Xuan C, Wang Y, et al. Association between ALMS 1 variants and early-onset coronary artery disease: a case-control study in Chinese population. Biosci Rep. 2020;40(9):BSR20193637.
   PubMedGoogle Scholar
• Xuan C, Li H, Tian QW, et al. Quantitative assessment of serum amino acids and association with early-onset coronary artery disease. Clin Interv Aging. 2021;16:465–474. doi: 10.2147/CIA.S298743.
   PubMed Web of Science ®Google Scholar
• Xuan C, Liu ZF, Wang Q, et al. Increased serum concentrations of asymmetric dimethylarginine (ADMA) in patients with early-onset coronary artery disease. Clin Chim Acta. 2017;464:195–199. doi: 10.1016/j.cca.2016.11.028.
   PubMed Web of Science ®Google Scholar
• Tian TT, Li H, Chen SJ, et al. Serum uric acid as an independent risk factor for the presence and severity of early-onset coronary artery disease: a case-control study. Dis Markers. 2018;2018:1236837. doi: 10.1155/2018/1236837.
   PubMed Web of Science ®Google Scholar
• Xuan C, Tian QW, Li H, et al. Serum fatty acids profile and association with early-onset coronary artery disease. Ther Adv Chronic Dis. 2021;12:20406223211033102. doi: 10.1177/20406223211033102.
   Web of Science ®Google Scholar
• Xuan C, Li H, Li LL, et al. Screening and identification of pregnancy zone protein and leucine-rich alpha-2-glycoprotein as potential serum biomarkers for early-onset myocardial infarction using protein profile analysis. Proteomics Clin Appl. 2019;13(3):e1800079.
   PubMed Web of Science ®Google Scholar
• Sheikh M, Tajdini M, Shafiee A, et al. Association of serum gamma-glutamyltransferase and premature coronary artery disease. Neth Heart J. 2017;25(7–8):439–445. doi: 10.1007/s12471-017-0964-5.
   PubMed Web of Science ®Google Scholar
• Huang Y, Luo J, Liu X, et al. Gamma-Glutamyltransferase and risk of acute coronary syndrome in young Chinese patients: a case-control study. Dis Markers. 2018;2018:2429160. doi: 10.1155/2018/2429160.
   PubMed Web of Science ®Google Scholar
• Singh KK, Kapoor A, Khanna R, et al. Serum gamma glutamyltransferase (GGT) in coronary artery disease: exploring the Asian Indian connection. Ann Card Anaesth. 2022;25(4):408–413. doi: 10.4103/aca.aca_62_21.
   PubMed Web of Science ®Google Scholar
• Aksakal E, Tanboga IH, Kurt M, et al. The relation of serum gamma-glutamyl transferase levels with coronary lesion complexity and long-term outcome in patients with stable coronary artery disease. Atherosclerosis. 2012;221(2):596–601. doi: 10.1016/j.atherosclerosis.2012.01.044.
   PubMed Web of Science ®Google Scholar